{"filings":[{"id":2051996,"accession_number":"0001193125-26-332870","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2026-08-04T20:19:19+00:00","items":["2.02","9.01"],"status":"ready","headline":"ATEC Q2 revenue $214M (+15% YoY); raises FY2026 adjusted EBITDA guidance to $140M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $214M (+15% YoY); surgical revenue $196M (+17% YoY) on 20% case volume growth.","GAAP net loss $26M; Non-GAAP net income $11M; adjusted EBITDA $36M (16.8% margin, +420 bps YoY).","Net new surgeon users +24%; ending cash $119M; positive free cash flow.","FY2026 revenue reaffirmed at ~$882M; adjusted EBITDA guidance raised to ~$140M (from ~$134M).","Expects at least $20M free cash flow for FY2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1000238,"accession_number":"0001193125-26-267552","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2026-06-11T20:13:07+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Alphatec shareholders approve 2026 equity incentive and ESPP plans","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 2026 Equity Incentive Plan (66.3M For, 28.1M Against) and 2026 Employee Stock Purchase Plan (94.5M For).","Plans become effective immediately; reserve shares and vesting terms set forth in the proxy statement and attached exhibits.","Director nominees all elected (e.g., McGinnis 93.2M For, Berkowitz 75.7M For); Deloitte ratified as auditor (118.3M For).","153.7M shares outstanding as of record date April 15; 118.4M shares represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92372,"accession_number":"0001193125-26-206530","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["1.01","1.02","2.02","2.03","9.01"],"status":"ready","headline":"ATEC Q1 rev $192M (+14%), surgical rev +17%; refinances debt with bank facility saving >$6M/yr","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $192M (14% YoY growth); surgical revenue $178M (+17%) driven by 21% case volume growth.","GAAP net loss $34M; non-GAAP net income $0M; adjusted EBITDA $21M (11% margin, up 460 bps YoY).","FY2026 total revenue guided to ~$882M (15% growth); surgical revenue ~$805M; adjusted EBITDA ~$134M (15%).","Entered $175M Term Loan A + $125M revolver led by JPMorgan; refinances prior debt, extends maturity to 2031.","New facility reduces interest expense >$6M annually, with potential >$35M total savings; SOFR+275bps at close."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":192108000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103189,"accession_number":"0001193125-26-088220","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Director Ward W. Woods retires from Alphatec board; unvested 4,269 RSUs accelerate","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ward W. Woods retires from Board effective Feb 27, 2026 for personal reasons; no disagreement with company.","Vesting acceleration of 4,269 unvested restricted stock units from June 11, 2025 grant.","Board size reduced to 7 from 8 following Woods' resignation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103188,"accession_number":"0001193125-26-067062","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alphatec FY2025 revenue $764M (+25% YoY); guides FY2026 ~$890M, raises EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 total revenue $764M (+25% YoY); GAAP net loss $143M; non-GAAP net income $8M.","Q4 2025 revenue $213M; adjusted EBITDA $33M (16% margin), expanding 390 bps YoY; positive Q4 free cash flow $8M.","FY2026 guidance: revenue ~$890M (+17%); adj. EBITDA ~$134M (15% of rev, up from $130M); FCF >=$20M.","Surgical revenue $190M in Q4 (+21% YoY); net new surgeon users +23% in Q4, +20% full year.","Valence intraoperative platform cleared and released; EOS Insight proliferation noted."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":764155000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103187,"accession_number":"0001193125-26-009910","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ATEC prelim FY2025 rev ~$764M (+25%), FY2026 outlook $890M; acquires OsteoAdapt distribution rights","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary FY2025 total revenue ~$764M (25% growth); surgical revenue grew 26% with volume up 24%.","FY2025 adjusted EBITDA reaffirmed at $91M; cash balance ~$161M; Q4 free cash flow expected $6-8M.","FY2026 outlook: total revenue $890M (17% growth), adjusted EBITDA ~$130M, positive free cash flow ~$20M.","Acquired exclusive U.S. distribution rights for Theradaptive's OsteoAdapt (rhBMP-2 biologic, Phase II for spinal fusion)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":764155000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119425,"accession_number":"0001193125-25-271197","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ATEC board member Jeffrey P. Rydin passes away at 59 after lengthy illness","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jeffrey P. Rydin, age 59, passed away on November 3, 2025 after a lengthy illness.","Rydin served on ATEC's Board of Directors since June 2017; Special Advisor from September 2016.","He had nearly 30 years of medical device experience, including senior roles at NuVasive, DePuy Spine, and Ellipse Technologies.","CEO Pat Miles highlighted Rydin's key role in ATEC's turnaround and sales channel transformation.","No replacement announced; company did not disclose any operational impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119424,"accession_number":"0001193125-25-258609","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ATEC reports Q3 revenue $197M (+30% YoY), raises FY2025 guidance to $760M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $197M, surgical revenue $177M (+31% YoY); EOS revenue $20M (+29%).","GAAP net loss $29M; non-GAAP net income $4M; adjusted EBITDA $26M (13% margin).","Free cash flow positive $5M in quarter, trailing twelve months also positive.","Full-year 2025 guidance raised: revenue $760M (from $742M), adjusted EBITDA $91M (from $83M).","Net new surgeon users grew 26% YoY, a key leading indicator."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":551227000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135979,"accession_number":"0000950170-25-100924","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ATEC Q2 revenue $186M (+27.5% YoY), raises FY revenue and EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Surgical revenue $168M (+29% YoY); total revenue $186M (+27.5% YoY).","GAAP net loss ($41M); non-GAAP net income $3M; adjusted EBITDA $23M (13% margin, +880 bps YoY).","Raised FY 2025 revenue guidance to $742M (prev. $734M) and adjusted EBITDA to $83M (prev. $78M).","Generated $5M free cash flow; trailing twelve months adjusted EBITDA $62M.","New surgeon adoption grew 21%, a key leading indicator."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":354724000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153011,"accession_number":"0000950170-25-086130","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Alphatec stockholders approve doubling authorized shares and equity plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to increase authorized common stock from 200M to 400M shares.","Amendment to 2016 equity incentive plan approved, increasing share pool to 38,383,333 shares.","All nine director nominees elected; Deloitte ratified as auditor; say-on-pay approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153010,"accession_number":"0000950170-25-061859","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ATEC Q1 revenue $169M (+22% YoY); raises FY guidance to $734M; refinances convertible debt to 2030","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Surgical revenue $152M (+24%), driven by 17% procedural volume growth and 18% new surgeon adoption increase.","GAAP net loss $52M; Adjusted EBITDA $11M (6% margin), improving 840 bps YoY.","FY2025 revenue guidance raised to ~$734M (from $732M) and adjusted EBITDA to ~$78M (from $75M).","Refinanced convertible debt extending maturity to 2030; ending cash $153M.","Free cash use improved $55M versus Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":169180000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153009,"accession_number":"0000950170-25-050434","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Alphatec reduces cash salaries 10-50% for NEOs, grants RSUs vesting in Aug and Dec 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash base salaries reduced by 10%, 25%, or 50% for NEOs and other executives.","Each NEO granted 3,866 to 21,751 RSUs based on March 31, 2025 closing price.","RSUs vest in two equal installments on Aug 5, 2025 and Dec 5, 2025.","Incentive compensation programs continue to reference pre-reduction base salary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171796,"accession_number":"0001193125-25-054786","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Alphatec issues $405M 0.75% convertibles due 2030, repurchases $253M of 2026 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Completed repurchase of $253.0M of its 0.75% convertible senior notes due 2026 on March 10, 2025.","Issued $405.0M of 0.75% convertible senior notes due 2030 (previously announced March 7, 2025).","Cap on shares deliverable upon conversion of new notes is 29,700,000 shares of common stock.","Company will settle conversions in cash and/or shares until authorized shares are increased."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171795,"accession_number":"0001193125-25-049998","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Alphatec issues $405M 0.75% convertible notes due 2030; repurchases $253M 2026 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $405M principal of 0.75% Convertible Senior Notes due 2030, including $55M from full exercise of initial purchasers' option.","Initial conversion price ~$15.54 per share; interest payable semi-annually, matures March 15, 2030.","Repurchased $253M aggregate principal of outstanding 2026 notes for ~$268.4M cash.","Entered capped call transactions costing ~$42.5M to reduce dilution on conversion; cap price $23.46 per share.","Notes are senior unsecured, redeemable after March 20, 2028 if stock price exceeds 130% of conversion price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171794,"accession_number":"0001193125-25-047166","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ATEC prices upsized $350M 0.75% convertible notes due 2030; to repurchase $253M 2026 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Pricing of $350M principal (upsized from $300M) of 0.75% convertible senior notes due 2030; initial conversion price ~$15.54 (32.5% premium).","Net proceeds estimated at $339M ($392.4M if full greenshoe of additional $55M exercised).","Will use ~$268.4M net proceeds to repurchase $253M aggregate principal of 0.75% convertible notes due 2026 in concurrent private transactions.","Entered into capped call transactions with cap price $23.46/share to reduce potential dilution upon conversion.","Offering expected to settle March 7, 2025; initial purchasers have 13-day option for additional $55M principal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171793,"accession_number":"0001193125-25-044094","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Alphatec announces $300M convertible notes offering due 2030, repurchases part of 2026 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Offers $300M aggregate principal of convertible senior notes due 2030; initial purchasers option for additional $50M.","Proceeds used to fund capped call transactions, repurchase outstanding 0.75% 2026 convertible notes, and general corporate purposes.","Concurrently repurchases a portion of its 0.75% convertible notes due 2026 in privately negotiated transactions.","Notes redeemable at ATEC's option after Mar 20, 2028 if stock exceeds 130% of conversion price.","Market information: ATEC estimates U.S. spine TAM at $8B, including $2B lumbar fusion and $1B lateral procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171792,"accession_number":"0000950170-25-027786","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ATEC FY2024 revenue $612M (+27% YoY); guides FY2025 rev ~$732M, positive FCF","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 total revenue $612M, +27% YoY; GAAP net loss $162M; non-GAAP adjusted EBITDA $31M (5% margin).","Q4 revenue $177M; Q4 adjusted EBITDA $21M (12% margin); generated $9M free cash flow; cash $139M.","Surgical revenue +28% in Q4; new surgeon users +20%; first surgery performed in Japan.","FY2025 guidance: revenue ~$732M (+20%), surgical ~$657M, EOS ~$75M, adj. EBITDA ~$75M, positive FCF."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":611562000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171791,"accession_number":"0000950170-25-004614","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alphatec reports prelim 2024 rev ~$611M (+27% YoY); guides 2025 rev $732M, positive FCF","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary full-year 2024 total revenue ~$611M (+27% YoY); surgical revenue up 29% to ~$544M.","Year-end 2024 cash ~$139M, up $58M from Q3, inclusive of $50M from term loan expansion.","2025 guidance: total revenue $732M (+20%), surgical $657M, EOS $75M; adjusted EBITDA ~$75M; positive FCF.","Issued 26,013 RSUs as inducement awards to 12 new non-executive employees.","Final Q4/FY2024 results scheduled for release on February 26, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":611562000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188794,"accession_number":"0000950170-24-119022","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"ATEC Q3 revenue $151M (+27%), raises FY guidance, adds $50M term loan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $151M, up 27% YoY; surgical revenue grew 30%.","GAAP net loss $40M; adjusted EBITDA $7.4M (5% margin).","Raised FY 2024 revenue guidance to $605M (from $602M) and adjusted EBITDA to ~$27M (from $25.5M).","Expanded existing term loan by $50M to total $200M capacity; pro-forma cash ~$128M.","Procedural volume grew 20%; new surgeon adoption up 19%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":434769000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205266,"accession_number":"0000950170-24-088609","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"ATEC Q2 revenue $146M (+25% YoY); raises FY2024 guidance to $602M rev, ~$25.5M adj EBITDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $146M (+25% YoY); surgical revenue +27%. GAAP net loss $41M; adjusted EBITDA $5.6M (4% margin).","Full-year 2024 guidance raised: total revenue expected $602M (from $601M); non-GAAP adj EBITDA ~$25.5M (from $23M).","Appointed Keith Valentine as independent director; former CEO of Orthofix and SeaSpine, 30+ years spine industry experience.","Launched EOS Insight integrating AI; record 244 surgeon training engagements; deployed $50M in revenue-generating assets.","Cash balance $100M; ended Q2 with liquidity to support growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":284050000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222150,"accession_number":"0000950170-24-073859","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Alphatec annual meeting: four directors depart, Altman gets accelerated vesting of 6,937 RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Four directors (Altman, Meynadier, Mowry, Tullis) not nominated for re-election; terms ended June 12, 2024.","Altman entered Vesting Acceleration Agreement: 6,937 unvested RSUs from August 2021 grant fully vest.","Stockholders elected nine directors; Mortimer Berkowitz III received 44.7M for vs 37.7M withheld.","Ratified Deloitte as auditor for FY2024 (103.8M for, 35.8K against).","Advisory say-on-pay approved: 69.8M for, 12.6M against, 49.8K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222149,"accession_number":"0000950170-24-054549","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ATEC Q1 revenue up 27% to $138M; raises FY 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Surgical revenue grew 30% YoY on 23% volume increase and 6% higher average revenue per procedure.","GAAP net loss of $48M; adjusted EBITDA loss of $3M (2% margin), improving 450 bps YoY.","Full-year revenue guidance raised to $601M (from $595M); adjusted EBITDA guidance raised to $23M (from $22M).","Ending cash balance of $144M; deployed ~$60M in revenue-generating assets during Q1.","CEO Pat Miles cites clear line of sight to $1B revenue with innovative spine portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":138477000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241668,"accession_number":"0000950170-24-033642","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Alphatec Holdings discloses holding 2024 Investor Day; no new material information in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed under Item 7.01 to disclose investor day presentation given March 19, 2024.","No financial results, guidance, or operational metrics provided in this 8-K.","Slides available on company website under Investors > Events & Presentations.","Information furnished, not filed; not incorporated by reference into SEC filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241667,"accession_number":"0000950170-24-021203","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alphatec reports FY2023 revenue $482M (+37% YoY); guides FY2024 revenue ~$595M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2023 revenue $482M, up 37% YoY; Q4 revenue $138M, surgical revenue growth 34%.","GAAP net loss of $187M for FY2023; Q4 net loss $49M.","FY2024 revenue guidance ~$595M, implying ~23% YoY growth; adjusted EBITDA margin expansion ~560 bps.","Adjusted EBITDA (updated definition) FY2023: ($9M) vs prior $4M; Q4: $2M.","Trained over 500 surgeons in 2023; surgeon users up 27% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":482262000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241666,"accession_number":"0000950170-24-002736","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Record preliminary 2023 revenue ~$481M (+37% YoY); 2024 guidance $595M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary FY2023 total revenue $481.1-482.7M, up ~37% YoY; surgical revenue grew 39-40%.","Q4 2023 revenue $136.8-138.4M (surgical $121.8-122.8M, EOS $15-15.6M).","FY2024 revenue guidance $595M ($530M surgical, $65M EOS), ~23-24% growth.","Surgical volume growth accelerated to 31% in FY2023 vs 25% in 2022.","Full FY2023 results and 2024 profitability guidance due Feb 27, 2024; LRP update on Mar 19."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":482262000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241665,"accession_number":"0000950170-24-000544","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Alphatec Holdings promotes Scott Lish to COO effective Jan 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Lish appointed Chief Operating Officer, effective January 1, 2024.","Lish previously served as SVP of R&D at Alphatec Spine since October 2020.","He joined Alphatec Spine in 2017 as VP of R&D, prior roles at NuVasive and Zimmer Dental.","Lish holds MS and BE in Mechanical Engineering from Dartmouth; BA in Engineering Sciences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259118,"accession_number":"0000950170-23-059413","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ATEC Q3 revenue up 32% to $118M; raises FY2023 adjusted EBITDA guidance to ~$3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $118M (+32% YoY); surgical revenue $104M (+32%), EOS $14M (+30%).","GAAP operating loss ($38M) but positive adjusted EBITDA of $2M, second consecutive quarter.","Raises FY2023 adjusted EBITDA guidance to ~$3M; revenue guidance unchanged at $472M (+35%).","Ended Q3 with $123M cash; secured $150M capital to invest in revenue-generating assets.","Inducement grants of 24,296 RSUs to 13 new non-executive employees."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":344292000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259117,"accession_number":"0001193125-23-264201","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2023-10-27T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Alphatec Holdings prices $150M public offering of 14.3M shares at $10.50 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$150M from 14.3M shares at $10.50; underwriters have 30-day option for 2.145M more.","Offering expected to close Oct 27, 2023; joint book-runners: Morgan Stanley, TD Cowen, Barclays, Stifel.","Executives, directors and certain shareholders subject to 90-day lock-up on sales.","Pricing represents significant dilution; no stated use of proceeds beyond general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259116,"accession_number":"0001193125-23-261657","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2023-10-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ATEC launches $150M stock offering; preliminary Q3 shows improved adjusted EBITDA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposed underwritten public offering of $150M common stock; underwriters have 30-day option to buy additional $22.5M.","Preliminary Q3 2023 net loss expected $42.4-43.2M, up ~$6M from $36.8M in Q3 2022.","Preliminary Q3 non-GAAP Adjusted EBITDA positive $1.5-2.3M, vs loss of $6.2M in Q3 2022.","Cash balance ~$123M at Sep 30, including $50M Braidwell term loan drawdown and $10M ATM proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259115,"accession_number":"0000950170-23-053803","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2023-10-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Alphatec appoints former Globus Medical CEO Demski to board, Valentine as special advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dave Demski, former Globus Medical CEO (2017-2022), appointed independent director effective Oct 17, 2023.","Keith Valentine, former Orthofix/SeaSpine CEO, appointed Special Advisor to the board.","Chairman Pat Miles highlights combined 50 years of spine leadership; ATEC positions as 'clinically focused spine-only company'.","Demski receives initial RSU grant of $300,000 vesting over 3 years, annual RSU of $150,000, and cash retainers up to $70,000 (Chair)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259114,"accession_number":"0000950170-23-053419","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2023-10-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ATEC raises FY2023 revenue guidance to ~$472M after Q3 preliminary revenue of $117.7-118.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $117.7-118.5M (+31-32% YoY), driven by lateral adoption momentum.","Surgical revenue $103.3-103.9M; EOS revenue $14.3-14.5M.","FY2023 revenue guidance raised to ~$472M from prior ~$462M.","Preliminary results; final Q3 earnings expected Nov 6, 2023 after market close."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":344292000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276385,"accession_number":"0000950170-23-038024","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ATEC Q2 revenue up 39% to $117M; raises FY2023 revenue guidance to $462M and adjusted EBITDA to ~$2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $117M (+39% YoY); surgical revenue $102M (+41%), EOS revenue $15M (+24%).","Positive adjusted EBITDA ~$1M, expanding margin 1,110 bps from prior year.","GAAP operating loss ($50M); gross margin 55% GAAP, 73% non-GAAP.","Surgical volume up 32%; average revenue per procedure up 7%.","Attracted 17 new employees with 12,772 RSUs granted as inducement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":226030000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276384,"accession_number":"0000950170-23-033728","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2023-07-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alphatec appoints Tyson Marshall as General Counsel; Hunsaker to lead Paris subsidiary","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Craig Hunsaker steps down as General Counsel/Corporate Secretary to relocate to Paris as General Manager of EOS imaging subsidiary for 15-18 months.","Tyson Marshall appointed General Counsel and Corporate Secretary effective July 19, 2023; previously VP Associate General Counsel since 2018.","Executive severance agreements signed with eight senior leaders (including CFO Koning) providing one-times annual target total cash compensation on involuntary termination without cause.","Hunsaker receives $5,000/month cost-of-living adjustment, housing up to €22,500/month rent, and tax equalization during assignment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294103,"accession_number":"0000950170-23-028307","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"ATEC stockholders elect 12 directors, approve equity plan share increases and auditor ratification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 12 director nominees elected; Berkowitz III and Blackford received ~12.9M and ~13.5M withheld votes.","Deloitte & Touche ratified as independent auditor for FY2023: 80.2M for, 78.6K against.","ESPP share reserve increased to 3,637,449 shares; 2016 Equity Plan reserve increased to 26,383,333 shares.","Non-binding advisory say-on-pay approved with 56.5M for; board adopts annual advisory vote frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294102,"accession_number":"0000950170-23-017916","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alphatec Q1 revenue up 54% to $109M; surgical revenue up 55%; adj EBITDA loss -$5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $109M (+54% YoY); surgical revenue +55%; EOS revenue $15M.","GAAP gross margin 65%, non-GAAP 72%; GAAP operating loss ($40M); Adj. EBITDA loss ($5M).","FY2023 guidance reaffirmed: revenue $450M (28% growth), surgical +30%, EOS $57M; adjuvant EBITDA break-even expected.","Surgical volume +40%; avg revenue per procedure +11%; acquired navigation robotics platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":109110000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294101,"accession_number":"0001193125-23-108488","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2023-04-20T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Alphatec prices $60M public offering of 4.3M shares at $14.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$60M from 4,285,715 shares priced at $14.00 per share.","Offering expected to close April 21, 2023; sole book-runner TD Cowen.","Proceeds for general corporate purposes including REMI robotic acquisition integration and R&D.","Directors and officers subject to 90-day lock-up on share sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294100,"accession_number":"0001193125-23-106427","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2023-04-19T23:59:59+00:00","items":["1.01","2.01","2.02","8.01","9.01"],"status":"ready","headline":"Alphatec acquires REMI robotic navigation system for $55M; raises FY2023 revenue guidance to $450M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired REMI Robotic Navigation System assets for $55M cash from Integrity Implants and Fusion Robotics.","Preliminary Q1 2023 total revenue $108-109.5M (+52% YoY); surgical revenue $93.2-94.3M (+53%).","Full-year 2023 revenue guidance raised to $450M (from $438M); surgical revenue expected ~$393M.","Cash and equivalents $117M as of March 31, 2023, up from $85M at Dec 31, 2022.","Granted 22,741 RSUs to eighteen new non-executive employees as inducement awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314717,"accession_number":"0000950170-23-007469","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Alphatec discloses $14M SVB deposit exposure; FDIC guarantees full access","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Approximately $14M in deposit accounts at failed Silicon Valley Bank; fully protected under joint Treasury-Fed-FDIC action.","Money market investments held through SVB as agent consist of U.S. government securities and are not part of FDIC receivership.","Company holds $100M fully-funded term loan with Braidwell and $35M drawn on MidCap revolving credit facility, both outside SVB.","Affirms cash and equivalents held outside SVB sufficient to meet operating needs for the foreseeable future."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314716,"accession_number":"0000950170-23-005104","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ATEC reports record FY2022 revenue of $351M, up 44%; guides FY2023 revenue $438M with adjusted EBITDA breakeven","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2022 revenue $351M (+44% YoY); Q4 revenue $106M (+43% YoY).","GAAP gross margin 66%, non-GAAP 70%; GAAP operating loss $147M; adjusted EBITDA loss $28M.","Q4 surgical volume +26%, avg revenue per procedure +18%; trained over 500 surgeons in 2022.","Secured non-dilutive capital of up to $275M; ending cash $85M.","FY2023 guidance: revenue ~$438M (+25%); adjusted EBITDA break-even expected."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":350867000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314715,"accession_number":"0000950170-23-000471","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"ATEC reports preliminary 2022 revenue ~$350M (+44%), guides 2023 revenue $438M, closes $150M term loan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2022 total revenue $350.1M-$351.1M, up ~44% YoY; Q4 revenue $105.2M-$106.2M.","2023 guidance: total revenue $438M (+25%), surgical $383M, EOS $55M; adjusted EBITDA break-even.","Closed $150M term loan from Braidwell ($100M funded, $50M delayed draw), 5-yr, SOFR+5.75%, interest-only.","Cash balance at Q4 end ~$85M; total liquidity ~$275M including existing revolver.","Surgical revenue Q4 grew 48-50% driven by PTP approach; surgical volume growth at least 25%."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":350867000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333124,"accession_number":"0000950170-22-021908","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alphatec Q3 revenue $90M (+43% YoY); surgical revenue +53%; guides FY22 $340M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $90M, up 43% YoY; surgical revenue up 53% to $79M; EOS revenue $11M.","GAAP gross margin 66%; non-GAAP 71%; GAAP operating loss ($35M); adjusted EBITDA ($6M) improved 870 bps YoY.","FY22 revenue guidance $340M (40% growth), including $46M EOS; surgical growth ~39%.","Surgical volume +32%, users +22%; launched first expandable interbody and Sigma Medialized access.","Closed $50M revolving credit facility with $25M accordion feature; cash $106M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":244923000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333123,"accession_number":"0000950170-22-019404","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2022-10-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ATEC pre-announces Q3 revenue $89-90M (+42-43% YoY) and raises FY22 growth guidance to ~40%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $89-90M (organic $78-78.8M) vs. $62.8M in Q3 2021; organic revenue growth 51-53%.","Procedural volume growth exceeded 30%, driven by PTP approach momentum.","Full-year 2022 total revenue growth now expected ~40%, up from prior 34% guidance.","Ended Q3 with cash balance of approximately $106 million.","Final Q3 results to be reported on November 3, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":244923000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333122,"accession_number":"0000950170-22-019239","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2022-10-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Alphatec enters $50M ABL credit facility; accordion up to $75M, matures 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Facility secured by accounts receivable (85% advance rate) and inventory (40%, capped at $15M or 50% of borrowing base).","Interest at Term SOFR + 3.50% per annum; maturity September 29, 2027 or 90 days before 2026 convertible notes maturity.","Proceeds used for fees, working capital, and general corporate purposes; $10M minimum liquidity covenant required.","Collateral includes substantially all assets except intellectual property; first-priority lien on subsidiary equity.","Lenders may increase commitments by up to $25M via additional tranches of at least $5M each, subject to conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350577,"accession_number":"0000950170-22-014765","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ATEC Q2 revenue $84M (+35%), raises FY2022 guidance to $325M (+34%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q2 revenue $84M, up 35% YoY (organic 30%); EOS imaging contributed $12M.","FY2022 revenue guidance raised to $325M, reflecting 34% growth vs 2021.","GAAP gross margin 66%, non-GAAP 70%; GAAP operating loss ($36M), adj. EBITDA ($8M).","Surgeon users up 23% YoY; average revenue per surgery grew 10%; sequential $3M EBITDA improvement.","Signed term sheet for $50M revolving credit facility with $25M accordion feature."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":155084000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367743,"accession_number":"0000950170-22-011753","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2022-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Alphatec stockholders elect directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 13 director nominees elected; votes for ranged from 49.0M (Berkowitz) to 56.6M (Altman, Mowry).","Ratification of Deloitte & Touche as auditor for FY2022: 74.6M for, 73k against, 54k abstain.","Advisory vote on executive compensation approved 37.6M for, 18.7M against (33% of votes cast opposed).","A quorum of 74.7M shares (73.5% of 101.7M outstanding) was present at the June 15, 2022 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367742,"accession_number":"0001564590-22-021227","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2022-05-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Alphatec Holdings holds Investor Day with long-term outlook presentation","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor Day held May 25, 2022, 8:15 a.m. to 12:00 p.m. PT at Carlsbad HQ and via webcast.","Event focuses on ATEC's spine surgery approach and long-term financial outlook.","Webcast replay available on Investor Relations section of company website.","No specific financial targets or guidance disclosed in the press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367741,"accession_number":"0001564590-22-018290","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ATEC Q1 revenue $71M (+61% YoY); raises FY22 guidance to $316M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $71M, up 61% YoY (organic 39%); GAAP gross margin 69%, non-GAAP 72%.","GAAP operating loss $41M; non-GAAP adjusted EBITDA loss $11M; cash $152M.","EOS imaging revenue exceeded $10M in Q1, with strong order book growth.","Full-year 2022 revenue guidance raised to $316M (30% growth), from prior ~$305M.","Lateral procedures drove ~40% of revenue growth; trained 100+ surgeons; surgeon users up 18% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":70933000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387093,"accession_number":"0001564590-22-008046","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ATEC reports record FY2021 revenue of $243.2M, up 68%; guides FY2022 to $305M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $74.0M; FY2021 revenue $243.2M, up 68% YoY (organic growth 50%).","GAAP operating loss $(128.1)M for FY2021; non-GAAP adjusted EBITDA $(28.1)M.","EOS imaging contributed $12.8M in Q4 revenue; placed systems drive portfolio adoption.","FY2022 revenue guidance of ~$305M (25% growth), including ~$45M from EOS imaging.","Surgeon users increased 23% in Q4 vs prior year; over 400 surgeons trained in 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":243212000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387092,"accession_number":"0001564590-22-000789","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ATEC preliminary FY2021 US organic revenue growth 50-51%; FY2022 total revenue guidance $305M (+26%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2021 total revenue $73.2M-$74.0M, US organic rev growth 41-42% YoY.","Full-year 2021 US organic revenue $211.8M-$212.3M, growth 50-51% YoY driven by PTP adoption.","FY2022 total revenue guidance $305M, ~26% growth; organic 22-23% plus ~$45M EOS.","EOS-related revenue exceeded expectations: Q4 $12.5M-$12.8M, FY $29.7M-$30.0M.","Company expects to report final Q4/FY2021 results on March 1, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":243212000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":405016,"accession_number":"0001564590-21-054496","cik":1350653,"company_name":"Alphatec Holdings, Inc.","ticker":"ATEC","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alphatec Q3 revenue $62.9M (+53% total, +29% organic); FY21 rev guidance ~$235M (+62%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $62.9M, up 53% YoY; organic revenue rose 29%; GAAP operating loss $35.1M.","Non-GAAP gross margin 72%; adjusted EBITDA loss $9.8M; cash balance $223.9M.","Lateral PTP technique drove >50% of Q3 revenue growth; surgeon users up 20% vs Q3 2020.","EOS imaging contributed >$11M in Q3; FY21 EOS revenue expected ~$26M.","Convertible debt raised net $188M; FY21 total revenue guidance ~$235M (+62% vs prior year)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":169250000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1208014991.6277137,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-04T23:59:59+00:00|405016"}